First generational breakthrough in liquid chromatography in 60 years,
produces 200x HPLC separation efficiency, speed and throughput
During a 30-minute test conducted
Earlier tests of TerraSep's companion Analytical scale Centrifugal Liquid Chromatograph (A-CLC) system demonstrated a separation efficiency 200x that of standard HPLC systems.
"This demonstration of the TerraSep system's efficiency in identifying and separating a target substance confirms it is a platform technology capable of replacing liquid chromatography (HPLC), currently the third most widely used scientific instrument for many laboratory and process applications worldwide," said TerraSep CEO
"The most significant finding of this test is that the data's peak amplitude in relation to its narrow width demonstrates the TerraSep system achieves and exceeds the level of selection specificity required in any industrial processing, quality assurance or analytical application," said
"The system's Improved separation specificity is the product of utilizing smaller stationary phase particles, which is made possible by our use of centrifugal force rather than high pressure to drive samples through test media," Kerr said. "In comparison, pressure-driven HPLC systems have reached a practical limit in decreasing particle size at 1.7 microns for analytical applications, and 10 microns for preparative and process scale systems."
The P-CLC system’s use of centrifugal force allows it to employ smaller-size stationary phase particles – 1.7 microns and smaller on a Preparative/Process scale - to create significant performance advantages compared with Preparative/Process liquid chromatography, according to Kerr, including:
Liquid chromatography is the world's third most widely utilized analytical technique, used to separate ions or molecules in a solution for purposes of purification, identification of trace amounts, or as part of a manufacturing process. Analytical High Performance Liquid Chromatography (HPLC) systems, equipment, and consumables exceeded
The company's business plan is to establish partnerships to apply its platform technology in specific industrial, pharmaceutical and medical market segments in exchange for license fees, royalties, manufacturing and services sales, including consumables and disposables.